Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia

Abstract

Relapsed childhood acute lymphoblastic leukemia (ALL) carries a poor prognosis, despite intensive retreatment, owing to intrinsic drug resistance1,2. The biological pathways that mediate resistance are unknown. Here, we report the transcriptome profiles of matched diagnosis and relapse bone marrow specimens from ten individuals with pediatric B-lymphoblastic leukemia using RNA sequencing. Transcriptome sequencing identified 20 newly acquired, novel nonsynonymous mutations not present at initial diagnosis, with 2 individuals harboring relapse-specific mutations in the same gene, NT5C2, encoding a 5′-nucleotidase. Full-exon sequencing of NT5C2 was completed in 61 further relapse specimens, identifying additional mutations in 5 cases. Enzymatic analysis of mutant proteins showed that base substitutions conferred increased enzymatic activity and resistance to treatment with nucleoside analog therapies. Clinically, all individuals who harbored NT5C2 mutations relapsed early, within 36 months of initial diagnosis (P = 0.03). These results suggest that mutations in NT5C2 are associated with the outgrowth of drug-resistant clones in ALL.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Relapse-specific mutations in NT5C2 alter enzymatic activity.
Figure 2: NT5C2 mutations confer chemoresistance to purine nucleoside analog treatment.

Similar content being viewed by others

Accession codes

Primary accessions

Sequence Read Archive

Referenced accessions

Ensembl

References

  1. Raetz, E.A. et al. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. J. Clin. Oncol. 26, 3971–3978 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Klumper, E. et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86, 3861–3868 (1995).

    Article  CAS  PubMed  Google Scholar 

  3. Li, J., Thompson, T.D., Miller, J.W., Pollack, L.A. & Stewart, S.L. Cancer incidence among children and adolescents in the United States, 2001–2003. Pediatrics 121, e1470–e1477 (2008).

    Article  PubMed  Google Scholar 

  4. Hunger, S.P. et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J. Clin. Oncol. 30, 1663–1669 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Pui, C.H. & Evans, W.E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166–178 (2006).

    Article  CAS  PubMed  Google Scholar 

  6. Chessells, J.M. et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br. J. Haematol. 123, 396–405 (2003).

    Article  PubMed  Google Scholar 

  7. Eapen, M. et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 107, 4961–4967 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gaynon, P.S. et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J. Clin. Oncol. 24, 3150–3156 (2006).

    Article  PubMed  Google Scholar 

  9. Hogan, L.E. et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 118, 5218–5226 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. DePristo, M.A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999–1005 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011).

    Article  CAS  PubMed  Google Scholar 

  15. Wei, X. et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442–446 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).

  17. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mullighan, C.G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235–239 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Shah, S.P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809–813 (2009).

    CAS  PubMed  Google Scholar 

  20. Bianchi, V. & Spychala, J. Mammalian 5′-nucleotidases. J. Biol. Chem. 278, 46195–46198 (2003).

    Article  CAS  PubMed  Google Scholar 

  21. Tozzi, M.G. et al. Nucleoside phosphotransferase activity of human colon carcinoma cytosolic 5′-nucleotidase. Arch. Biochem. Biophys. 291, 212–217 (1991).

    Article  CAS  PubMed  Google Scholar 

  22. Tozzi, M.G. et al. Cytosolic 5′-nucleotidase/phosphotransferase of human colon carcinoma. Adv. Exp. Med. Biol. 309B, 173–176 (1991).

    Article  CAS  PubMed  Google Scholar 

  23. Walldén, K. et al. Crystal structure of human cytosolic 5′-nucleotidase II: insights into allosteric regulation and substrate recognition. J. Biol. Chem. 282, 17828–17836 (2007).

    Article  PubMed  Google Scholar 

  24. Spychala, J., Chen, V., Oka, J. & Mitchell, B.S. ATP and phosphate reciprocally affect subunit association of human recombinant high Km 5′-nucleotidase. Role for the C-terminal polyglutamic acid tract in subunit association and catalytic activity. Eur. J. Biochem. 259, 851–858 (1999).

    Article  CAS  PubMed  Google Scholar 

  25. Pieters, R. et al. Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. Leuk. Res. 16, 873–880 (1992).

    Article  CAS  PubMed  Google Scholar 

  26. Galmarini, C.M. et al. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98, 1922–1926 (2001).

    Article  CAS  PubMed  Google Scholar 

  27. Galmarini, C.M. et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br. J. Haematol. 122, 53–60 (2003).

    Article  CAS  PubMed  Google Scholar 

  28. Mazzon, C. et al. Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. Biochem. Pharmacol. 66, 471–479 (2003).

    Article  CAS  PubMed  Google Scholar 

  29. Yang, J.J. et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112, 4178–4183 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Diouf, B. et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med. 17, 1298–1303 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gallier, F. et al. Structural insights into the inhibition of cytosolic 5′-nucleotidase II (cN-II) by ribonucleosidse 5′-monophosphate analogues. PLOS Comput. Biol. 7–e1002295 (2011).

  32. Jordheim, L.P. et al. Identification and characterization of inhibitors of cytoplasmic 5′-nucleotidase cN-II issued from virtual screening. Biochem. Pharmacol. 85, 497–506 (2013).

    Article  CAS  PubMed  Google Scholar 

  33. Smith, M. et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J. Clin. Oncol. 14, 18–24 (1996).

    Article  CAS  PubMed  Google Scholar 

  34. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010).

  36. Robinson, J.T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Kumar, P., Henikoff, S. & Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073–1081 (2009).

    Article  CAS  PubMed  Google Scholar 

  39. Totrov, M. & Abagyan, R. The contour-buildup algorithm to calculate the analytical molecular surface. J. Struct. Biol. 116, 138–143 (1996).

    Article  CAS  PubMed  Google Scholar 

  40. Totrov, M. & Abagyan, R. Rapid boundary element solvation electrostatics calculations in folding simulations: successful folding of a 23-residue peptide. Biopolymers 60, 124–133 (2001).

    Article  CAS  PubMed  Google Scholar 

  41. Dervieux, T. et al. HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin. Chem. 48, 61–68 (2002).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the members of the Carroll laboratory as well as L.B. Gardner, M. Karajannis and I. Osman for their critical review of the manuscript. We gratefully acknowledge the Children's Oncology Group (COG) for patient specimens, the New York University Genome Technology Center for expert assistance with Illumina (B. Baysa) and Roche 454 (E. Venturini) deep-sequencing experiments (supported in part by US National Institutes of Health/National Center for Research Resources (NIH/NCRR) grant S10 RR026950-01), P. Grace, J.D. Ernst and M.R. Phillips (New York University School of Medicine) for expression and lentiviral vectors and F. Tsai, M.R. Phillips and S.M. Brown for technical guidance. This work was supported by US NIH grants R01 CA140729 and R21 CA152838-02 to W.L.C. and New York University Cancer Center Support Grant 5 P30 CA16087-30 in collaboration with the New York University Genome Technology Center. Additional support was provided by grants from the National Cancer Institute to COG, including U10 CA98543 (COG Chair's grant), U10 CA98413 (COG Statistical Center) and U24 CA114766 (COG Specimen Banking). J.A.M. is supported by NIH grant T32 CA009161. L.E.H. was supported by the American Society of Hematology and St. Baldrick's Foundation. S.P.H. is the Ergen Family Chair in Pediatric Cancer.

Author information

Authors and Affiliations

Authors

Contributions

J.A.M., L.E.H., J.J.Y., J.Z., R.L.L., T.C., W.E.E., D.J.M., C.E.M. and W.L.C. planned experiments. J.A.M., L.E.H., J.J.Y., S.D., J.P.P. and D.J.M. performed experiments and analyzed data. J.W., Z.T., P.Z., S.L. and C.E.M. performed sequencing and analyzed sequence data. T.C. performed molecular modeling. S.P.H. and E.A.R. provided patient samples and clinical data. J.A.M. and W.L.C. wrote the manuscript. W.L.C. coordinated the study. All authors discussed the results and reviewed the manuscript.

Corresponding author

Correspondence to William L Carroll.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Note, Supplementary Figures 1–8 and Supplementary Tables 1–4 (PDF 1309 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer, J., Wang, J., Hogan, L. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 45, 290–294 (2013). https://doi.org/10.1038/ng.2558

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.2558

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer